Duane J Roth

US Patent:

RE38081, Apr 15, 2003

Filed:

Feb 2, 2001

Appl. No.:

09/776144

Inventors:

Nicholas Simon Faithfull - La Jolla CA 92037
Peter E. Keipert - San Diego CA 92130
Duane J. Roth - La Jolla CA 92037
Ronald M. Hopkins - Escondido CA 92029

International Classification:

A61M 3700

US Classification:

604 401, 604 614

Abstract:

A method for hemodiluting a patient is disclosed which includes the steps of administering a biocompatible oxygen carrier in conjunction with surgery or organ ischemia or infarct while assessing the patients PvO or other oxygenation indices, and administering to the patient additional oxygen carrier or autologous blood in response to the PvO value if necessary to maintain the PvO at or above the desired level.

US Patent:

58657843, Feb 2, 1999

Filed:

Jun 7, 1995

Appl. No.:

8/484166

Inventors:

Nicholas Simon Faithfull - La Jolla CA
Peter E. Keipert - San Diego CA
Duane J. Roth - La Jolla CA
Ronald M. Hopkins - Escondido CA

Assignee:

Alliance Pharmaceutical Corp. - San Diego CA

International Classification:

A61K 4700

US Classification:

604 4

Abstract:

A method for hemodiluting a patient is disclosed which includes the steps of administering a biocompatible oxygen carrier in conjunction with surgery or organ ischemia or infarct while assessing the patient's PvO. sub. 2 or other oxygenation indices, and administering to the patient additional oxygen carrier or autologous blood in response to the PvO. sub. 2 value if necessary to maintain the PvO. sub. 2 at or above the desired level.

US Patent:

54512050, Sep 19, 1995

Filed:

Jun 3, 1994

Appl. No.:

8/253414

Inventors:

Duane J. Roth - La Jolla CA
Peter E. Keipert - San Diego CA
Nicholas S. Faithfull - The Woodlands, GB2
Thomas F. Zuck - Cincinnati OH
Jean G. Riess - Nice, FR

Assignee:

Alliance Pharmaceutical Corp. - San Diego CA

International Classification:

A61K 4700

US Classification:

604 6

Abstract:

A method for facilitating autologous blood use by a patient facing a loss of blood, comprising the steps of removing and preferably storing a portion of the patient's blood, intravenously administering a biocompatible liquid in sufficient quantity to substantially maintain the patient's hemodynamic stability, wherein the liquid comprises an effective oxygen-delivery enhancing amount of a biocompatible synthetic oxygen carrier, after which the patient undergoes a loss of blood, and then readministering blood to the patient, preferably the stored blood. In one embodiment, the biocompatible liquid further comprises a hemodiluent and the hemodiluent is administered separately from the oxygen carrier.

US Patent:

60077743, Dec 28, 1999

Filed:

Jun 18, 1998

Appl. No.:

9/099731

Inventors:

Nicholas Simon Faithfull - La Jolla CA
Peter E. Keipert - San Diego CA
Duane J. Roth - La Jolla CA
Ronald M. Hopkins - Escondido CA

Assignee:

Alliance Pharmaceutical Corp. - San Diego CA

International Classification:

A61M 114
A61M 3700

US Classification:

422 44

Abstract:

A method for treating conditions associated with ischemia or infarct is disclosed which includes the steps of administering a biocompatible non-blood oxygen carrier while monitoring one or more oxygenation indices to maintain oxygenation of the patient's tissues at or above a predetermined level.

US Patent:

53443934, Sep 6, 1994

Filed:

Feb 28, 1992

Appl. No.:

7/843518

Inventors:

Duane J. Roth - La Jolla CA
Peter E. Keipert - San Diego CA
Nicholas S. Faithfull - Normanton by Bottesford, GB2
Thomas F. Zuck - Cincinnati OH
Jean G. Riess - Nice, FR

Assignee:

Alliance Pharmaceutical Corp. - San Diego CA

International Classification:

A61K 4700

US Classification:

604 4

Abstract:

A method for facilitating autologous blood use by a patient facing a loss of blood, comprising the steps of removing and preferably storing a portion of the patient's blood, intravenously administering a biocompatible liquid in sufficient quantity to substantially maintain the patient's hemodynamic stability, wherein the liquid comprises an effective oxygen-delivery enhancing amount of a biocompatible synthetic oxygen carrier, after which the patient undergoes a loss of blood, and then readministering blood to the patient, preferably the stored blood. In one embodiment, the biocompatible liquid further comprises a hemodiluent and the hemodiluent is administered separately from the oxygen carrier.